News|Articles|March 15, 2020
Monograph Development: Why and When to Participate
Author(s)J. Mark Wiggins, Joseph A. Albanese
This article explores a proactive advocacy approach that a bio/pharmaceutical company may take through participation in the development of new and revised monographs in the various pharmacopoeias.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The Regulatory Crucible: Risk, Resource Drain, and the Hidden Trade-Offs of the CNPV Pilot Program
2
New Targets for Clinical Trials in the European Union
3
Leveraging AI/ML to Reduce Risk in Drug Development: Part One
4
Molecular Dynamics and Quantum Calculations: AAPS Thermo Fisher Interview, Part Two
5
